骨科生物制剂文献趋势:11年回顾性系统综述
该研究系统回顾了2009至2019年间9本骨科核心期刊中关于富血小板血浆、骨髓抽吸物、脂肪来源细胞和羊膜细胞的474篇文章,发现发文量逐年增长且以富血小板血浆为主,但报告标准高度异质,呼吁建立最低报告标准并提升研究质量。
要点
- 骨科生物制剂文献11年间持续增长,2018至2019年增幅最大。
- 富血小板血浆占全部文献51.5%,且占91.5%的1级临床研究。
- 仅28.5%使用报告方案的文章采用已建立的算法,报告异质性大。
核心结论
- 骨科生物制剂研究兴趣持续增长,但报告异质性大,需建立最低报告标准和更高质量研究。
研究设计与样本
- 系统综述,证据等级4级,通过PubMed系统检索2009至2019年9本知名骨科期刊中关于富血小板血浆、骨髓抽吸物、脂肪来源细胞和羊膜细胞治疗肌肉骨骼疾病的文章。
主要发现
- 共纳入474篇文章,其中临床132篇、非临床271篇、综述71篇。
- 富血小板血浆244篇(51.5%),骨髓抽吸物146篇(30.8%),脂肪来源细胞72篇(15.2%),羊膜细胞12篇(2.5%)。
- 各主题年度发文量最大增长均出现在2018至2019年。
- 《美国运动医学杂志》总发文量占34.2%、临床发文量占50.0%,并占所有富血小板血浆文章的44.3%。
- 《骨科研究杂志》总发文量占24.9%居第二,非临床发文量占41.0%最高。
关键数值与推荐
- 富血小板血浆占所有1级临床研究的91.5%。
- 骨髓抽吸物、脂肪来源细胞和羊膜细胞文章中超过一半为3级或更低证据等级。
- 207篇使用某种报告方案的文章中,59篇(28.5%)使用已建立算法,125篇(60.4%)使用自有方案。
临床怎么用
- 临床医生应了解骨科生物制剂证据以低级别为主且报告标准不一,应用时需谨慎解读相关文献。
局限性
- 仅纳入9本骨科期刊,可能遗漏其他期刊发表的相关文献。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of "orthobiologics" or regenerative therapies in orthopaedic surgery has grown in recent years. Particular interest has been raised with regard to platelet-rich plasma, bone marrow aspirate, adipose-derived cells, and amniotic cells. Although studies have analyzed outcomes after orthobiologic treatment, no study has analyzed how the literature as a whole has evolved. PURPOSE: To evaluate trends in platelet-rich plasma, bone marrow aspirate, adipose-derived cells, and amniotic cell publications and to assess how these might inform efforts to establish minimum reporting standards and forecast future use. STUDY DESIGN: Systematic review; Level of evidence, 4. METHODS: A database was compiled systematically using PubMed to identify articles published between 2009 and 2019 within 9 prominent orthopaedic journals and pertaining to the use of platelet-rich plasma, bone marrow aspirate, adipose-derived cells, and amniotic cells in the treatment of musculoskeletal conditions. Included articles were classified as clinical, nonclinical (translational or basic science), or review, and a variety of study parameters were recorded for each. Additional queries were performed to identify articles that utilized minimum reporting standards. RESULTS: A total of 474 articles (132 clinical, 271 nonclinical, 71 review) were included, consisting of 244 (51.5%) platelet-rich plasma, 146 (30.8%) bone marrow aspirate, 72 (15.2%) adipose-derived cells, and 12 (2.5%) amniotic cells. The greatest annual increase in publications for each orthobiologic topic was from 2018 to 2019. The American Journal of Sports Medicine demonstrated the highest number of overall (34.2%) and clinical (50.0%) publications, and accounted for 44.3% of all platelet-rich plasma publications. The Journal of Orthopaedic Research accounted for the second highest overall number of publications (24.9%) and highest nonclinical publications (41.0%). Platelet-rich plasma accounted for 91.5% of all level 1 clinical studies, while much greater than half of bone marrow aspirate, adipose-derived cells, and amniotic cell publications were level 3 or lower. Out of the 207 articles that used some form of reporting protocol, 59 (28.5%) used an established algorithm and 125 (60.4%) used their own. CONCLUSION: Interest in orthobiologics continues to grow, as evidenced by an increasing trend in publications over an 11-year period. However, current reporting on orthobiologic formulations is largely heterogeneous, emphasizing the need for minimum reporting standards and higher-quality studies.
引用
- Obana KK, Schallmo MS, Hong IS, et al. Current Trends in Orthobiologics: An 11-Year Review of the Orthopaedic Literature. Am J Sports Med. 2021. PMID: 34528456. doi:10.1177/03635465211037343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。